HU-210 is an analog of the tricyclic benzopyran $\Delta^9$-THC. Originally this compound was thought to be selective for CB$_1$, however currently it is known that HU–210 binds equally to both CB$_1$ and CB$_2$ receptors. HU-210 intraperitoneal injection in rats, starting at 20 $\mu$g/kg, results in a dose-dependent inhibition of plasma growth hormone, follicle-stimulating hormone and luteinizing hormone. Plasma adrenocorticotropic hormone and corticosterone levels revealed a dose-dependent activation of the pituitary-adrenal axis after acute exposure to HU-210. Plasma prolactin levels reflected a biphasic action of HU-210: the 4 $\mu$g/kg dose resulted in high prolactin levels and the 20 and 100 $\mu$g/kg doses caused decrease in the levels of this hormone. HU-210 induces a set of endocrine alterations closely related to those described for natural cannabinoids such as $\Delta^9$-THC. HU-210 is a more potent inhibitor with doses 50-200 times lower than those required for $\Delta^9$-THC.\(^4\)

**Preparation Instructions**

HU-210 is soluble in DMSO at 20 mg/ml. It is insoluble in water.

**Storage/Stability**

Store at –20 °C under nitrogen, desiccated.
References


AH 03/03